Brian Harvey Willis

Brian Harvey Willis

Auto-generated profile, based on publicly available information

Brian Harvey Willis

Institute of Applied Health Research, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2018 in JAMA
Verified
Journal Article
Closed access
PDF file
MMMatthew D. F. McInnes
Matthew D. F. McInnes
DMDavid Moher
David Moher
BTBrett D. Thombs
Brett D. Thombs
TMTrevor A. McGrath
Trevor A. McGrath
PBPatrick M. Bossuyt
Patrick M. Bossuyt
BWBrian H. Willis
Brian H. Willis
Importance Systematic reviews of diagnostic test accuracy synthesize data from primary diagnostic studies that have evaluated the accuracy of 1 or more index tests against a reference standard, provide estimates of test performance, allow comparisons of the accuracy of different tests, and facilitate the identification of sources of variability in test accuracy. Objective To develop the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagnostic test accuracy guideline as a stand-alone extension of the PRISMA statement. Modifications to the PRISMA statement reflect the specific requirements for reporting of systematic reviews and meta-analyses of diagnostic test accuracy studies and the abstracts for these reviews. Design Established standards from the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network were followed for the development of the guideline. The original PRISMA statement was used as a framework on which to modify and add items. A group of 24 multidisciplinary experts used a systematic review of articles on existing reporting guidelines and methods, a 3-round Delphi process, a consensus meeting, pilot testing, and iterative refinement to develop the PRISMA diagnostic test accuracy guideline. The final version of the PRISMA diagnostic test accuracy guideline checklist was approved by the group. Findings The systematic review (produced 64 items) and the Delphi process (provided feedback on 7 proposed items; 1 item was later split into 2 items) identified 71 potentially relevant items for consideration. The Delphi process reduced these to 60 items that were discussed at the consensus meeting. Following the meeting, pilot testing and iterative feedback were used to generate the 27-item PRISMA diagnostic test accuracy checklist. To reflect specific or optimal contemporary systematic review methods for diagnostic test accuracy, 8 of the 27 original PRISMA items were left unchanged, 17 were modified, 2 were added, and 2 were omitted. Conclusions and Relevance The 27-item PRISMA diagnostic test accuracy checklist provides specific guidance for reporting of systematic reviews. The PRISMA diagnostic test accuracy guideline can facilitate the transparent reporting of reviews, and may assist in the evaluation of validity and applicability, enhance replicability of reviews, and make the results from systematic reviews of diagnostic test accuracy studies more useful.

14 August 2020 in BMJ
Verified
Journal Article
Closed access
PDF file
JSJean-Paul Salameh
Jean-Paul Salameh
PBPatrick M Bossuyt
Patrick M Bossuyt
TMTrevor A McGrath
Trevor A McGrath
BTBrett D Thombs
Brett D Thombs
CHChristopher J Hyde
Christopher J Hyde
MMMatthew D F McInnes
Matthew D F McInnes
Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision making process in evidence based medicine. Although such studies are regarded as high level evidence, these reviews are not always reported completely and transparently. Suboptimal reporting of DTA systematic reviews compromises their validity and generalisability, and subsequently their value to key stakeholders. An extension of the PRISMA (preferred reporting items for systematic review and meta-analysis) statement was recently developed to improve the reporting quality of DTA systematic reviews. The PRISMA-DTA statement has 27 items, of which eight are unmodified from the original PRISMA statement. This article provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices.

15 June 2017 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
BWBrian H. Willis
Brian H. Willis
RRRichard D. Riley
Richard D. Riley
An important question for clinicians appraising a meta‐analysis is: are the findings likely to be valid in their own practice—does the reported effect accurately represent the effect that would occur in their own clinical population? To this end we advance the concept of statistical validity—where the parameter being estimated equals the corresponding parameter for a new independent study. Using a simple (‘leave‐one‐out’) cross‐validation technique, we demonstrate how we may test meta‐analysis estimates for statistical validity using a new validation statistic, Vn, and derive its distribution.We compare this with the usual approach of investigating heterogeneity in meta‐analyses and demonstrate the link between statistical validity and homogeneity. Using a simulation study, the properties of Vn and the Q statistic are compared for univariate random effects meta‐analysis and a tailored meta‐regression model, where information from the setting (included as model covariates) is used to calibrate the summary estimate to the setting of application. Their properties are found to be similar when there are 50 studies or more, but for fewer studies Vn has greater power but a higher type 1 error rate than Q. The power and type 1 error rate of Vn are also shown to depend on the within‐study variance, between‐study variance, study sample size, and the number of studies in the meta‐analysis. Finally, we apply Vn to two published meta‐analyses and conclude that it usefully augments standard methods when deciding upon the likely validity of summary meta‐analysis estimates in clinical practice. © 2017 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.

1 September 2008 in Family Practice
Verified
Journal Article
Open access
PDF file
BWBrian H Willis
Brian H Willis
When applying study results to their practice, the clinician is constrained by a number of factors, perhaps none more important than spectrum bias, which describes the effect a change in patient case mix may have on the performance of a test. Although the literature contains notable examples of spectrum bias, the emphasis has been to demonstrate its existence and its implications on study design rather than how it affects the clinician. Here a definition is proposed before considering it from a GP's perspective. As a patient's probability of disease is in part determined by the test's result, having reliable estimates of a test's performance is imperative to making good decisions on patient management. Knowing how the test performs on a patient usually means knowing its performance within a particular subgroup. Unfortunately, studies tend to report weighted average estimates of performance across broad populations. Such estimates may be inaccurate at an individual level and at a population level with the overall performance of the test in practice varying significantly from the average estimate reported, owing to differing case mixes. To avert such problems, investigators should design studies to evaluate tests over all relevant subgroups, and where this is not possible, to be explicit about the case mix in the study sample. Furthermore, GPs should endeavour to know both individual patients and practice populations as a whole in terms of demographics and co-morbidities before applying study results to their patients.

20 February 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
KTKonstantinos A. Toulis
Konstantinos A. Toulis
BWBrian H. Willis
Brian H. Willis
TMTom Marshall
Tom Marshall
BKBalachadran Kumarendran
Balachadran Kumarendran
KGKrishna Margadhamane Gokhale
Krishna Margadhamane Gokhale
KNKrishnarajah Nirantharakumar
Krishnarajah Nirantharakumar
Context: Empagliflozin was found to decrease mortality in patients with type 2 diabetes mellitus (T2DM) and a prior cardiovascular disease (CVD) event. Objectives: To establish whether these benefits can be replicated in a real-world setting, should be expected with the use of dapagliflozin, and apply to T2DM patients at low risk of CVD. Design: General practice, population-based, retrospective cohort study (January 2013 to September 2015). Setting: The Health Improvement Network database. Participants: A total of 22,124 T2DM patients (4444 exposed to dapagliflozin; 17,680 unexposed T2DM patients) matched for age, sex, body mass index, T2DM duration, and smoking. Main Outcome Measures: The primary outcome was all-cause mortality (high and low risk for CVD) in the total study population, expressed as the adjusted incidence rate ratio (aIRR) with 95% confidence intervals (CIs). As a secondary analysis in the low-risk population, all-cause mortality and incident CVD were considered. Results: Patients with T2DM exposed to dapagliflozin were significantly less likely to die of any cause (aIRR: 0.50; 95% CI: 0.33 to 0.75; P = 0.001). Similarly, in low-risk patients, death from any cause was significantly lower in the cohort exposed to dapagliflozin (aIRR: 0.44; 95% CI: 0.25 to 0.78; P = 0.002). The difference in the risk of incident CVD did not reach statistical significance between groups in low-risk patients (aIRR: 0.89; 95% CI: 0.61 to 1.31; P = 0.546). Conclusions: Patients with T2DM who were exposed to dapagliflozin had a lower risk of death from any cause irrespective of baseline CVD status.

31 October 2016 in Diabetologia
Verified
Journal Article
Open access
PDF file
George E. DafoulasGeorge E. Dafoulas
George E. Dafoulas
KTKonstantinos A. Toulis
Konstantinos A. Toulis
DMDougall Mccorry
Dougall Mccorry
BKBalachadran Kumarendran
Balachadran Kumarendran
GTG.Neil Thomas
G.Neil Thomas
KNKrishnarajah Nirantharakumar
Krishnarajah Nirantharakumar
Aims/Hypothesis The aim of this research was to explore the relationship between incident epilepsy and type 1 diabetes in British participants. Methods Using The Health Improvement Network database, we conducted a retrospective, open-cohort study. Patients who were newly diagnosed with type 1 diabetes mellitus at the age of ≤40 years were identified and followed-up from 1 January 1990 to 15 September 2015. These patients, identified as not suffering from epilepsy at the time of diagnosis, were randomly matched with up to four individuals without type 1 diabetes mellitus, based on age, sex and participating general practice. A Cox regression analysis was subsequently performed using Townsend deprivation index, cerebral palsy, head injury and learning disabilities as model covariates. Results The study population consisted of a total of 24,610 individuals (4922 with type 1 diabetes and 19,688 controls). These individuals were followed up for a mean of 5.4 years (approximately 132,000 person-years of follow up). Patients with type 1 diabetes were significantly more likely to be diagnosed with epilepsy during the observation period compared with controls (crude HR [95% CI]: 3.02 [1.95, 4.69]). The incidence rate was estimated to be 132 and 44 per 100,000 person-years in patients and controls, respectively. This finding persisted after adjusting for model covariates (adjusted HR [95% CI]: 3.01 [1.93, 4.68]) and was also robust to sensitivity analysis, excluding adult-onset type 1 diabetes mellitus. Conclusions/Interpretation Patients with type 1 diabetes are at approximately three-times greater risk of developing epilepsy compared with matched controls without type 1 diabetes. This should be considered when investigating seizure-related disorders in patients with type 1 diabetes mellitus.